What You Should Know:
– Certis Oncology Solutions, a translational science and emerging technology leader in preclinical oncology research, is pleased to announce the commercial launch of CertisOI Assistant™, an innovative chatbot tool designed to enhance the efficiency and effectiveness of cancer research.
– This cutting-edge research tool leverages artificial intelligence/machine learning (AI/ML) and OpenAI’s ChatGPT language model to provide researchers unparalleled insights into cancer models and drug response, bringing greater precision to early drug development decisions.
CertisAI™: Revolutionizing Precision Cancer Medicine with Predictive AI/ML Insights
CertisAI™, developed by Certis Oncology Solutions, is a patent-pending predictive artificial intelligence and machine learning (AI/ML) platform that transforms cancer research and treatment development. It is the first and only commercially available, validated AI/ML system capable of predicting therapeutic efficacy by identifying complex gene expression signatures correlating with drug response. By leveraging unique tumor gene expression profiles, CertisAI™ enables pharmaceutical researchers to develop novel therapies and clinicians to identify personalized treatment options for specific cancers.
The CertisOI Assistant, an advanced natural language interface, enhances accessibility to genomic and drug sensitivity data derived from thousands of cancer research models. These include Certis’ patient-derived xenograft (PDX) models and public resources such as the Cancer Cell Line Encyclopedia (CCLE). The Assistant integrates with CertisAI™ Predictive Oncology Intelligence™, offering:
- Data-driven insights for research model selection and biomarker strategy development.
- Efficient in silico validation of therapeutic approaches.
- Seamless generation of charts, graphs, and downloadable data summaries to support collaborative research.
These AI-enabled systems streamline the analysis of complex data, enabling researchers to accelerate scientific investigation and facilitate the development of personalized cancer treatments. Researchers can query the CertisOI Assistant to rapidly interpret data, visualize results, and share insights, significantly enhancing efficiency.
Peter Ellman, President and CEO of Certis Oncology, emphasized, “The launch of CertisOI Assistant represents a critical step in advancing precision cancer medicine. By empowering researchers with robust tools for analyzing and interpreting data, we accelerate the discovery of effective, individualized cancer therapies.”
CertisAI™ and CertisOI Assistant exemplify the innovative application of AI/ML in oncology, setting a new standard for precision medicine and therapeutic development.
